1. Clinical & Scientific Overview
Lacosamide IP & Sumatriptan / Rizatriptan / Flunarizine (TIP-MED-000417, Reference Code [11.28]-CMP147) is classified under
Neurology & Antiepileptic Medicines (Ch 11) as a Broad-Spectrum Antiepileptics, Bipolar Mood Stabiliser & Migraine Prophylaxis.
Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).
Co-indexed per approved Author Decisions DEC-08 (8A) and DEC-12 (12A; from HTML [11.21] & [11.28]). Lacosamide (slow Na+ channel inactivator, 50–200 mg BD) and Sumatriptan/Rizatriptan acute migraine triptans.
Standard approved strengths (refer to comparative context)
3. Mechanism of Action & Pharmacodynamics
Co-indexed per approved Author Decisions DEC-08 (8A) and DEC-12 (12A; from HTML [11.21] & [11.28]). Lacosamide (slow Na+ channel inactivator, 50–200 mg BD) and Sumatriptan/Rizatriptan acute migraine triptans.
4. Therapeutic Indications & Evidence-Supported Uses
- Focal & generalised epilepsy, Lennox–Gastaut syndrome, Bipolar I depressive maintenance (Lamotrigine — preferred in women of childbearing age over Valproate), and chronic migraine prophylaxis (Topiramate 50–100 mg/day)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Co-indexed per approved Author Decisions DEC-08 (8A) and DEC-12 (12A; from HTML [11.21] & [11.28]). Lacosamide (slow Na+ channel inactivator, 50–200 mg BD) and Sumatriptan/Rizatriptan acute migraine triptans.
Administration & Meal Timing: With or without food; maintain high daily water intake (>=2–2.5 L/day) with Topiramate to prevent calcium phosphate kidney stones. | Once daily at bedtime (initial titration) or BD maintenance.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Comparative pharmacokinetic profile co-indexed under [11.28].
Renal: Halve Topiramate dose if CrCl <70 mL/min. Hepatic: Reduce Lamotrigine dose by 50% in Child-Pugh B and 75% in Child-Pugh C.
Renal: Halve Topiramate dose if CrCl <70 mL/min. Hepatic: Reduce Lamotrigine dose by 50% in Child-Pugh B and 75% in Child-Pugh C.
Renal: Halve Topiramate dose if CrCl <70 mL/min. Hepatic: Reduce Lamotrigine dose by 50% in Child-Pugh B and 75% in Child-Pugh C.
7. Contraindications, Precautions & High-Risk Warnings
- LAMOTRIGINE LIFE-THREATENING SJS/TEN RASH & TOPIRAMATE ANGLE-CLOSURE GLAUCOMA / ACIDOSIS: Rapid titration of Lamotrigine (or failing to halve dose with Valproate) causes fatal Stevens–Johnson Syndrome / TEN (1% paediatric, 0.3% adult). Topiramate causes acute bilateral secondary angle-closure glaucoma, oligohidrosis (paediatric heatstroke), metabolic acidosis, and cleft lip teratogenicity.
Key Clinical Precautions: Renal: Halve Topiramate dose if CrCl <70 mL/min. Hepatic: Reduce Lamotrigine dose by 50% in Child-Pugh B and 75% in Child-Pugh C.
8. Adverse Effects Profile
- Lamotrigine: Benign rash (10%), dizziness, diplopia, insomnia. Topiramate: Paraesthesia (tingling fingers/toes), weight loss/anorexia, 'word-finding' cognitive slowing, nephrolithiasis.
- Stevens–Johnson Syndrome / TEN & DRESS (Lamotrigine — Weeks 2–8), acute myopia with secondary angle-closure glaucoma (Topiramate — within 1 month), hyperchloraemic metabolic acidosis, nephrolithiasis.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Valproate potently inhibits UGT1A4 glucuronidation, DOUBLING Lamotrigine half-life to ~60h (mandatory 50% dose reduction!)
- Carbamazepine, Phenytoin, Phenobarbitone & Ethinylestradiol OCPs double Lamotrigine clearance
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical parameters per parent class monograph [11.28].
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: STOP Lamotrigine and seek immediate medical care at the first sign of ANY skin rash, fever, or mouth ulcers; if you miss Lamotrigine for >5 days, do NOT resume your full dose; with Topiramate, drink 8–10 glasses of water daily and report sudden eye pain/blurred vision immediately.
- Meal & Clock Timing Instruction: With or without food; maintain high daily water intake (>=2–2.5 L/day) with Topiramate to prevent calcium phosphate kidney stones. (Once daily at bedtime (initial titration) or BD maintenance.)
- Missed Dose Protocol: Take as soon as remembered unless close to next scheduled dose; never double the dose.
- Geriatric Dispensing Pearl: Schedule: Schedule H | NLEM 2022: Yes (Lamotrigine) | Compendia: NFI 7th Ed 2026 / NLEM 2022 / ILAE Guidelines
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Lamotrigine Dispersible/Oral Tablets: 25 mg, 50 mg, 100 mg, 200 mg. Topiramate Film-Coated Tablets / Sprinkle Capsules: 25 mg, 50 mg, 100 mg.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [11.27]-C144 Carbidopa [FDC] (with Pramipexole comparison/co-therapy) — Dopamine Precursor + Peripheral DOPA Decarboxylase Inhibitor & No
- [11.27]-CMP145 Ropinirole Hydrochloride & Trihexyphenidyl Hydrochloride IP — Dopamine Precursor + Peripheral DOPA Decarboxylase Inhibitor & No
- [11.28]-C146 Topiramate — Broad-Spectrum Antiepileptics, Bipolar Mood Stabiliser & Migraine
- [11.8] Sodium Valproate / Divalproex Sodium (Valproic Acid) — Broad-Spectrum Antiepileptic & Mood Stabiliser (Enhances GABAergi